UK small-cap RNS · 11 Dec 2025

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus the ones that are part of a situation. Not investment advice.

Sort: Newest · Largest companies

12:00

RC365 Holding RCGH £7.5m
Half-year Results Results
Revenue nearly doubled to HK$11.9m and the loss narrowed to HK$4.1m, but gross margin fell from 89.2% to 39.3%, cash halved to HK$5.9m and the company flags going concern uncertainty.

Balance-sheet stress / refinancing outlook positivefirst since Oct 2023 +0.0% on the day

Moved: new: RC3.0 App and virtual banking launch – Launch preparation; targeted early Q1 2026 · new: Credit card and lending rollout – Money Lenders Licence acquired; rollout targeted Q4 2025 · new: Liquidity and going concern – Cash HK$5.9m; going concern uncertainty flagged
09:50

Pollen Street POLN £547m
Update Statement on 2025 AGM Voting Results Results
Pollen Street Group Limited ("Pollen Street Group" or the "Company") today provides an update regarding its Annual General Meeting held on 12 June 2025 ("AGM").

+1.1% on the day
08:59

Empyrean Energy EME £3.5m
Half-year Results Results
Empyrean Energy PLC / Index: AIM / Epic: EME / Sector: Oil & Gas

first since Oct 2023 −7.0% on the day
07:00

NCC Group NCC £250m
Preliminary audited results for the year 30/09/25 Results
Adjusted EBITDA of £40.6m is down from £42.1m but in line with the Board's expectations. H2 revenue improved on H1, and FY25 group revenue still fell 2.6%.

in line −0.6% on the day

Moved: Profitable growth with flat to low single digit revenue growth in FY25: on_track → missed – FY25 group revenue fell 2.6% in constant currency excluding non-core disposals, short of the flat to low single-digit growth promised, though Adjusted EBITDA was in line with expectations. · Achieve the Group's medium-term financial goals: pending → on_track – The Board reiterates confidence in the medium-term financial goals, with FY26 EBITDA expected to grow faster than revenue. · Escode sale review: Escode Review ongoing, no outcome yet → Review ongoing, no outcome yet
07:00

Allergy Therapeutics AGY £285m
Prelim Results and publication of Annual Report Results
("Allergy Therapeutics" or the "Group" or the "Company")

−0.5% on the day
07:00

RWS Holdings RWS £542m
Final Results Results
Not a profit warning: adjusted PBT of £60.4m landed within the guidance already given. The negatives are the year-on-year fall, the £88.0m goodwill impairment and the dividend cut, not a guidance downgrade.

outlook positivefirst since Oct 2023 +5.7% on the day

Moved: New strategy and operating model: New structure launched 1 October; on track → Model launched; efficiency plan enhanced, 10% productivity target